EGFR基因突变指导TKI的治疗策略进展资料.ppt

* 应该选用何种检测方法？ * In particular, blood based (serum/plasma) testing is particularly attractive due to the ease of accessibility to samples, but the sensitivity of the methods currently used mean that identifying EGFR mutation positive patients from blood is still challenging ? AstraZeneca research suggests that of the patients who are identified as mutation positive by analysing their tumour, approximately 50% can be identified as mutation positive by analysing circulating free DNA (cfDNA) in blood. Data demonstrated a 0% false positive rate. ? For this reason, blood based testing may not replac